Effect of combined treatment with radiation and low dose etoposide on cell survival

Anticancer Research

Volumn 21, Issue 1 A, 2001, Pages 325-328

  Shigematsu, N ^a   Kawata, T ^a   Ihara, N ^a   Kawaguchi, O ^a   Kutsuki, S ^a   Ishibashi, R ^a   Kubo, A ^a   Ito, H ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Etoposide; Radiosensitization

Indexed keywords

ETOPOSIDE; RADIOSENSITIZING AGENT;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL KILLING; CELL SURVIVAL; CHEMOSENSITIVITY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; COMBINED MODALITY THERAPY; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETOPOSIDE; FEMALE; HUMANS; NEOPLASMS; OVARIAN NEOPLASMS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; URINARY BLADDER NEOPLASMS;

EID: 0035060810     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Radiation response of mammalian cells grown in culture
2. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen
3. Breast tumor cell lines from pleural effusions
4. Establishment of a human ovarian clear cell carcinoma cell line (RMG1) and its single cell cloning -With special reference to the stem cell of the tumor
5. Hypoxic cell radiosensitizers: Expectations and progress in drug development
6. Concurrent daily cisplatin and radiotherapy in locally advanced squamous cell carcinoma of head and neck arid bronchus
7. Combined low dose cisplatin and radiation therapy in advanced head and neck cancer
8. Chemotherapy of small cell carcinoma of lung with VP16-213
9. The podophyllotoxin derivatives VP16.213 and VM26
10. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial
11. Oral etoposide therapy in stage III-IV ovarian carcinoma
12. Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma
13. Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus
14. Single- and double-strand DNA breakage and repair in human sung adenocarcinoma cells exposed to etoposide and teniposide
15. Effect of combined treatment of HeLa S3 cells with radiation and Etoposide on cell survival
16. The suppressive effect of etoposide on recovery from sublethal radiation damage in Chinese hamster V79 cells
17. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide
18. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase
19. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
20. Topoisomerase IIα and topoisomerase IIβ genes: Characterization and mapping human chromosomes 17 and 3 respectively
21. Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cells